Pei-Hsiu Huang, M.D.

Interventional Cardiologist: California State License No. A126295

Sutter Medical Group Cardiology
2800 L Street, 6th Floor
Sacramento CA 95816
Phone: (916)733-1788
E-mail:
pei-hsiu.huang@sutterhealth.org

Research Office
Sutter Institute for Medical Research
2801 Capitol Avenue Suite 210
Sacramento, CA 95816
Phone: (916) 887-4698
Fax: (916) 887-4751

CURRICULUM VITAE
Hospital Appointments:
Interventional Cardiologist, Cardiac Cath Lab Director
SMCS
Sacramento, CA
Aug 2013 to Present

Medical Staff: Department of Medicine
Barnes-Jewish Hospital
St. Louis, MO
Dec 2009 to Jun 2011

Medical Staff: Department of Medicine
Atlanta VA Medical Center
Decatur, GA
Jul 2007 to Jun 2008

Education:
Coursework towards Master of Population Health Sciences
Washington University School of Medicine
St. Louis, MO
2010 to 2011
Doctor of Medicine
Emory University, School of Medicine
Atlanta, GA
2001 to 2005

Coursework in Biochemistry and Laboratory Research in Genetics
University of Oxford
Oxford, England
1999 to 2000
Bachelor of Science in Biology with Honors
Emory University
Atlanta, GA
1997 to 2001

Postdoctoral Trainings:
Structural Heart and Peripheral Vascular Interventions Fellowship
Brigham and Women’s Hospital, Harvard Medical School
Boston, MA
2012 to 2013

Interventional Cardiology Fellowship
Brigham and Women’s Hospital, Harvard Medical School
Boston, MA
2011 to 2012
Cardiovascular Disease Fellowship
Barnes-Jewish Hospital, Washington University School of Medicine
St. Louis, MO
2008 to 2011

Postdoctoral Trainings Cont.:
J. Willis Hurst Internal Medicine Residency Program
Emory University School of Medicine
Atlanta, GA
2005 to 2008

Certifications:
Diplomate in Interventional Cardiology, American Board of
Internal Medicine, 2012
 Diplomate in Cardiovascular Disease, American Board of Internal
Medicine, 2011
 Diplomate in Adult Comprehensive Echocardiography, National
Board of Echocardiography, 2010
 Diplomate in Internal Medicine, American Board of Internal
Medicine, 2008
 United States Medical Licensing Examination– Step 3, 2006
 United States Medical Licensing Examination– Step 2 CK, 2004
 United States Medical Licensing Examination– Step 2 CS, 2004
 United States Medical Licensing Examination– Step 1, 2003

Licensure:
Georgia Composite Medical Board, #059169 (Inactive)
Missouri State Board of Registration for the Healing Art,
#2009034197 (Inactive)
Commonwealth of Massachusetts Board of Registration in
Medicine, #246974 (Inactive)
Medical Board of California, #A126295

Languages:
 English (Primary)
 Mandarin (Conversational)
 Taiwanese (Conversational)

Honors:
Transcatheter Cardiovascular Therapeutics 2009 Impella Fellows
Scholarship
PGY-1 Class Elected Representative, 2005-2006
University of Oxford Junior Year Abroad Scholarship, 1999
Barry M. Goldwater Scholar, 1999
Summer Undergrad Research Experience (SURE), 1998

Committee Service:
ACC Championing Care for Patients with Aortic Stenosis,
Planning Committee Member, 2013 to Present
Professional Societies:
American College of Cardiology, 2008 to Present
Society for Cardiovascular Angiography and Interventions, 2011
to Present
 

Case Presentations:
“Impella 2.5: Just the Right Fit” Transcatherter Cardiovascular
Therapeutics, 2009, San Francisco, CA 2009.
“Valves, Leaks, and D Femoral Dissection…” If You Build It
They Will Come: How to Build a TAVR Center. ACC.13 Clinical
Focus Session. San Francisco, CA 2013.

Reviews:

· Huang P and Bhatt DL. Adjunctive pharmacotherapy in thrombotic coronary lesions. lnterv Cardiol Clin 2013;2(2):375-387.

· Huang P and Eisenhauer AC. Transcatheter Aortic Valve Replacement Using Edwards SAPIEN Transcatheter Heart Valves. Cardiol Clin 2013;31(3):337-350.

Book Chapters:

· Huang P. (2012) The Comprehensive Transthoracic Echocardiographic Examination. In R Rasalingam (Ed.), The Washington Manual of Echocardiography. Philadelphia, PA: Lippincott Williams & Wilkins.

· Huang P and Resnic FR. (2012) Closure of Percutaneous Vascular Access. In P Lanzer (Ed.), Catheter­ Based Cardiovascular Interventions: Knowledge-Based Approach. Berlin, Germany: Springer-Verlag.

· Huang P and Faxon DP. Native and Prosthetic Valve Stenosis. ln JK Min, DS Berman, & J Leipsic (Eds.), Multimodality Imaging for Transcatheter Aortic Valve Replacement. Heidelberg, Germany: Springer. (In press)

Case Reports:

· Huang P, Kosmidou I, McDaniel MC, Samady H. Gath of the Month: A 48-Year-Old Female Presents With Acute Chest Discomfort. Cardiosource Web Site, American College of Cardiology Foundation. Available at http://www.cardiosource.com/casestudies/casestudy.asp?studyid=1135. Accessed January 31, 2008.

· Gosev I, Nascimben L, Huang P, Mauri L, Steigner M, Mizuguchi A, Shah AM, Aranki S. Right Ventricular Perforation and Pulmonary Embolism with Polymethylmethacrylate Cement after Percutaneous Kyphoplasty. Circulation 2013;127(11):1251-53.

Letters to the Editor:

Huang P, Zajarias A, Lasala JM. Bleeding avoidance strategies and percutaneous coronary intervention. JAMA 2010; 304(10):1068.

Published Abstracts:

· Patel SJ, Huang P, Oshinski JN, Parks WJ, Brummer ME, Socotow J, Pettigrew RI. Differences in collateral flow before and after surgical repair of coarctation of the aorta examined by magnetic resonance imaging. J Cardiovasc Magn Reson 2003; 5:173-4.

· Huang P, EIHammali RM, Chamsuddin AA, Bailey JL. Malignant Hypertension Following Endovascular Abdominal Aortic Aneurysm Repair. American Soceity of Nephro!ogy Abstract Book for Renal Week 2007

· Topkara VK, Yeung M, Huang P, Hadi AM, Joseph SM, Schilling JD, Sylvestry SC, Moazami N, Wang IW, Ewald GA. Heart-lung transplantation may confer protection from developing transplant coronary artery disease: an analysis of the United Organ Network Sharing database. J Heart Lung Transplant 2011; 30(4) Suppl:S12-3. Oral Presentation, International Society tor Heart & Lung Transplantation 31st Annual Meeting and Scientific Sessions. San Diego, California, April 2011.

· Kerrigan JL, Yeung M, Sodhi S, Huang P, Maniar H, Zajarias A Racial differences in rates of aortic valve replacement in patients with severe aortic stenosis. J Am Coll Cardiol 2012; 59(13s1):E2041.

· Huang P, AraDjo GN, Govindarajulu US, Wainstein MV, Resnic FS, McCabe JM. Comparison of two risk models in predicting the incidence of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 2013; 61(10_S):E1738. Oral Presentation, American College of Cardiology ACC.13 Annual Scientific Session, San Francisco, California, March 2013

Presented Abstracts (Not Published):

· Huang P, Swords WE, Birkness KA, Quinn FA. A system for the identification of differentially expressed genes in biofilms.Presented at Summer Undergraduate Research Experience, Emory University, Atlanta, Georgia, 1998.

· Huang P, Patel SJ, Oshinski JN, Pettigrew Rt, Brummer ME, Fyfe DA, Wu G, Parks WJ. Differences in collateral flow before and after surgical repair of coarctation of the aorta examined by magnetic resonance imaging.Oral Presentation at The 35th Annual Meeting of the Southeast Pediatric Cardiology Society, ChateauE/an, Braselton, Georgia, 2002.

· Bedoya P, Patel D, Cobb J, Lee P, Friedman R, Maalouf S, Bhadkamkar N, Huang P, Shah S, Aggarwal G, Krivitsky E, Kats S, Dantzler D, Cunningham K. Improving exercise counseling rates. Presented at the Institute for Heathcare Improvement 2CYh Annual Nation Forum on Quality Improvement in Healthcare, Nashville, Tennessee, 2008.

· Kerrigan J, Yeung M, Huang P, Zajarias A. Ethnic differences in patients referred for aortic valve replacement for severe aortic stenosis. Presented at the American College of Physicians, Missouri Chapter, 2010 Annual Scientific Meeting, Osage Beach, Missouri, 2010.

Original Articles:

· Birkness KA, Swords WE, Huang P, White EH, Dezzutti CS, Lal RB, Quinn FD. Observed differences in vlrulence-associated phenotypes between a human clinical isolate and a veterinary isolate of Mycobacterium avium. Infect lmmun 1999; 67:4895-901.

· Huang P, Pryde FE, Lester D, Maddison RL, Sorts RH, Hickson ID, Louis EJ. SGS1 is required for telomere elongation in the absence of te!omerase. Curr Bio/ 2001; 11:125-9.

· Huang P. Characterizing function of the mycobacterial alpha-crystamn homolog expressed in latent mycobacterium tuberculosis. Honors Thesis. Emory University, 2001.

· Rasalingam R, Johnson SN, Bilhorn KR, Huang P, Makan M, Moazami N, Perez JE. Transthoracic assessment of continuous-flow left ventricular assist devices. J Am Soc Echocardiogr 2011; 24(2):135-48.

· Huang P, Yeung M, Lasala JM, Cox DA, Bowman TS, Starzyk RM, Dawkins KO. Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE Program. J Intent Cardiof 2011; 24(3):232-40.

· Huang P, Kim CX, Lerman A, Cannon CP, Dai D, Laskey W, Peacock WF, Hernandez, AF, Peterson ED, Smith EE, Fonarow GC, Schwamm LH, Bhatt DL. Trends in smoking cessation counseling: experience from Get With The Guidelines. Clin Cardiol 2012; 35(7):396-403.

· Huang P, Croce KJ, Bhatt DL, Resnic FS. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery following coronary stent implantation. Crit Pathw Cardiol 2012;11(4):177-185.

· Mohan AV, Fazel R, Huang P, Chen YC, Howard DH. Changes in the use and geographic variation in percutaneous coronary intervention for stable ischemic heart disease following publication of the COURAGE trial. (Submitted)

· Yeung M, Kerrigan JL, Sodhi S, Huang P, Novak E, Maniar H, Zajarias A. Rada! differences in rates of aortic valve replacement in patients with severe aortic stenosis. (Accepted Am J Cardio

· McCabe JM, Huang P, Riedl LA, Devireddy SR, Grondefl J, Connors AC, Davidson MJ, Eisenhauer AC, Welt FGP. Incidence and implications of idiopathic thrombocytopenia following transcatheter aortic valve replacement with the Edwards Sapien valves: a single center experience. (Submitted)

· Huang P and Araujo GN, Govindarajulu US, Connors AC, Resnic FS, McCabe JM. Performance of two risk models in predicting the incidence of contrast-induced nephropathy after percutaneous coronary intervention. (Manuscript in preparation)

Research Experience:

Charactering and comparing virulence– associated phenotypes of Mycobacterium avium strains.

Mentor: Frederick Quinn, Ph.D.

National Center for Infectious Diseases, Tuberculosis/Mycobacteriology Branch, Pathogenesis Laboratory, Centers for Disease Control and Prevention

Jun 1996 to Aug 1997

Screening for differential gene expression during Mycobacterium avium biofilm formation.

Mentor: Frederick Quinn, Ph.D.

National Center for Infectious Diseases, Tuberculosis/Mycobacteriology Branch, Pathogenesis Laboratory, Centers for Disease Control and Prevention

Jun 1998 to Aug 1998

Constructing plasmid vectors for analysis of sigma factor expression in Mycobacterium tuberculosis.

Mentor: Frederick Quinn, Ph.D.

National Center for Infectious Diseases, Tuberculosis/Mycobacteriology Branch, Pathogenesis Laboratory, Centers for Disease Control and Prevention

Jun 1999 to Sept 1999

Screening for genes involved in meiotic recombination in msh4 deficient Saccharomyces cerevisiae.

Mentor: Rhona Barts, Ph.D.

Department of Biochemistry, Institute of Molecular Medicine, University of Oxford

Oct 1999 to Jun 2000

Examining telomere regeneration In telomerase deficient Saccharomyces cerevisiae.

Mentor: Edward Louis, Ph.D.

Department of Biochemistry, Institute of Molecular Medicine, University of Oxford

Oct 1999 to Jun 2000

Research Experience Cont.:

Characterizing the role of alpha-crystallin protein in Mycobacterium tuberculosis latency survival.

Mentor: Frederick Quinn, Ph.D.

National Center for Infectious Diseases, Division of AIDS, STD and Tuberculosis Laboratory Research, Tuberculosis/Mycobacteriology Branch, Pathogenesis Laboratory, Centers for Disease Control and Prevention

Aug 2000 to Apr 2001

Differences in collateral flow before and after surgical repair of coarctation of the aorta examined by magnetic resonance imaging.

Mentor: John Oshinski, Ph.D.

Frederick Philips Magnetic Resonance Research Center at Emory University

Jun 2002 to Sept 2002

Characterization of signal transduction related to binding of renin/prorenin to the renin receptor.

Mentor: W. Robert Taylor, M.D., Ph.D.

Division of Cardiology, Emory University School of Medicine

Jun 2006 to Aug 2006

Clinical Trials:

· Sub-investigator, Sutter Medical Center, Sacramento: ABSORB III - A Clinical Evaluation of AbsorbTM BYS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native coronary Artery Lesions, Abbott Vascular, Inc., 2013 to 2014

· Sub-investigator, Sutter Medical Center, Sacramento: ABSORB IV- A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions, Abbott Vascular, Inc, 2014 to Present

· Principal Investigator, Sutter Medical Center, Sacramento: EVOLVE SHORT DAPT- A single-arm study designed to assess the safety of3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCl) with the SYNERGYTM Evcrolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), Boston Scientific Corporation, 2016 to Present

· Principal Investigator, Sutter Medical Center Sacramento: PARTNER 3 -A Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcather Heart Valve in Low Risk Patients, Edwards Lifesciences, 2016 to Present

· Principal Investigator, Sutter Medical Center Sacramento: PARTNER 3  AVIV -A Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcather Heart Valve in Patients with a Failing Aortic Bioprosthetic Valve, Edwards Lifesciences, 2017 to Present

Clinical Trials Cont.:

· Sub-Investigator, Sutter Medical Center Sacramento: PORTICO– A study to evaluate the Portico™ Transcather Heart Valve in patients with symptomatic severe native aortic stenosis, who are considered high or extreme surgical risk, Abbott Vascular, Inc., 2016 to Present

· Principal Investigator, Sutter Medical Center Sacramento: SAPIEN XT Post-Approval Study to evaluate lnger-term safety and effectiveness of the SAPIEN XT Transcatheter Heart Valve (THY) in the pulmonic position for the intended patient population (especially pediatric) when used as indicated with all valve sizes, Edwards Lifesciences, 2017 to 2018

· Principal Investigator, Sutter Medical Center Sacramento: RADIANCE– HTN is a randomized, double-blind, sham controlled, 2– cohort study designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct population of hypertensive subject, ReCor Medical, 2016 to 2022

· Sub-Investigator, Sutter Medical Center Sacramento: MedStar Low Risk TAVR, a study to assess the safety and feasibility of Transcatheter Aortic Valve Replacement (TAVR) with commercially available bioprothesis in elderly patients with severe, symptomatic aortic stenosis (AS) who are low-risk (STS score: S3%) for surgical aortic valve replacement (SAVR), MedStar Cardiovascular Research Institute, 2017 to Present

· Sub-Investigator, Sutter Medical Center Sacramento: AEGIS-I A Phase 2b, multicenter, randomized, placebo-controlled, dose ranging study to investigate the safety and tolerability of multiple dose administration of CSL 112 in subjects with Acute Myocardial Infaction, CSl Behring LLC, 2015 to 2016

· Sub-Investigator, Sutter Medical Center Sacramento: Cardiomems, A post approval study of the CardioMEMS™ HF System, Abbott Vasclar, Inc., 2015 to 2017

· Principal Investigator, Sutter Medical Center Sacramento: Clinical performance of the investigational gem Hemochrom® 100 in populations ages 18 years and older, Accriva Diagnostics, 2018 to Present

· Sub-Investigator, Sutter Medical Center Sacramento: AMPLATZER™ PFO post approval study, 2018 to Present

· Sub-Investigator, Sutter Medical Center Sacramento: SUMMIT, A clinical trial to evaluate the safety and effectiveness of using the Tendyne Mitral Valve system for the treatment of Symptomatic Mitral Regurgitation, Tendyne Holding Inc., 2018 to Present

· Principal Investigator, Sutter Medical Center Sacramento: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcathter Valve Repair System compared to Abbott MitraClip in patients with mitral regurgitation , Edwards Lifesciences, LLC, 2019 to Present

Clinical Trials Cont.:

· Principal Investigator, Sutter Medical Center Sacramento: Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN Patients Treated with the Tricuspid ValvE Repair System Pivotal (TRILUMINATE Pivotal) Protocol # ABT-CIP-10249, Abbott Vascular Inc., 2020 to Present

· Principal Investigator, Sutter Medical Center Sacramento: A Pivotal, Multicenter, Blinded, Sham Procedure– Controlled Trial of Renal Denervation by the Peregrine System™ Kit in Subjects with Hypertension (The TARGET BPI Trial), Ablative Solution, INC. 2020 to 2022

Humanitarian Use Devices:

· PK Papyrus Covered Coronary Stent System HUD, Biotronik

· Amplatzer™  Post Infarct Muscular VSD Occluder, Abbott